Portal:Disease/COVIDPathways
From WikiPathways
(Difference between revisions)
(New page: {| style="margin: 10px; background-color:#eaf2ee" |width=100px; cell padding=50px|{{#pwImage:Pathway:WP4846|250px||SARS-CoV-2 and COVID-19 Pathway}} |width=100px|{{#pwImage:Pathway:WP4853|...) |
Current revision (17:55, 15 September 2020) (view source) (Redirecting to Portal:COVID-19) |
||
| (59 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | {| style="margin: 10px; background-color:# | + | #REDIRECT [[Portal:COVID-19]] |
| + | |||
| + | __NOTOC__ | ||
| + | |||
| + | {|style="margin: 10px;" | ||
| + | |width=800px| | ||
| + | <br/><big><font color="#407F7F" size="5">Welcome to the COVID-19 Pathway Collection</font></big><br/><br/> | ||
| + | <p>This special subset of disease pathways is being highlighted during the current COVID-19 crisis. This content is released under a CC0 waiver to be freely used, reused and distributed. Let us know if you add a new pathway or want to recommend one for this collection.</p> | ||
| + | <p>The current list of authors and contributors of content of this portal: [[User:Fehrhart|Friederike Ehrhart]], [[User:AlexanderPico|Alex Pico]], [[User:Khanspers|Kristina Hanspers]], [[User:Amber|Amber Koning]], [[User:Rex_D_A_B|Rex D A B]], [[User:Penny|Penny Nymark]], [[User:DeSl|Denise Slenter]], [[User:C.F.Thorn|Caroline Thorn]], [[User:Jdoijen|Jordi Doijen]], the Reactome project, [[User:Evelo|Chris Evelo]], [[User:L Dupuis|Lauren Dupuis]], [[User:Conroy_lipids|Matthew Conroy]], [[User:Mkutmon|Martina Kutmon]], [[User:Marvin M2|Marvin Martens]], and many more.</p> | ||
| + | |||
| + | <p>We also thank the authors of all the cited articles (recursively).</p> | ||
| + | {{#section:Help:Authors|covid-help}} | ||
| + | |||
| + | |{{#imgLink:Page1-601px-COVID19-Disease-Map-project-icon.pdf.jpg|230|right|Part of the <a href="https://covid.pages.uni.lu/">COVID-19 Disease Map</a> project<p>A paper about this project was published in <a href="http://dx.doi.org/10.1038/s41597-020-0477-8">Scientific Data</a>. </p>|external|https://covid.pages.uni.lu/|COVID19 Disease Map}} | ||
| + | |} | ||
| + | |||
| + | == SARS-CoV-2 Pathways == | ||
| + | |||
| + | {| style="margin: 10px; background-color:#AFDCDE" | ||
|width=100px; cell padding=50px|{{#pwImage:Pathway:WP4846|250px||SARS-CoV-2 and COVID-19 Pathway}} | |width=100px; cell padding=50px|{{#pwImage:Pathway:WP4846|250px||SARS-CoV-2 and COVID-19 Pathway}} | ||
| + | Collaborative project for curation of biological processes involved in the COVID-19 disease after SARS-Cov-2 infection. | ||
| + | |width=100px|{{#pwImage:Pathway:WP4860|250px||Hijack of Ubiquitination by SARS-CoV-2}} | ||
| + | SARS-CoV-2 includes a novel Orf10 that interacts with muliple members of the Cullin 2 ubiquitin ligase complex. | ||
| + | |width=100px|{{#pwImage:Pathway:WP4868|250px||Type I Interferon Induction and Signaling During SARS-CoV-2 Infection}} | ||
| + | The induction and signaling of type I interferon with specific SARS-CoV-2 protein and relevant drug. | ||
| + | |width=100px|{{#pwImage:Pathway:WP4927|250px||COVID-19, thrombosis and anticoagulation}} | ||
| + | |- | ||
| + | |} | ||
| + | {| style="margin: 10px; background-color:#AFDCDE" | ||
| + | |width=100px|{{#pwImage:Pathway:WP4876|250px||Activation of NLRP3 Inflammasome by SARS-CoV-2}} | ||
| + | Orf3a from SARS-CoV has been shown to bind TRAF3 and activate the NLRP3 inflammasome. | ||
| + | |width=100px|{{#pwImage:Pathway:WP4883|250px||SARS-CoV-2 and Angiotensin-converting enzyme 2 (ACE2) receptor : Molecular mechanisms and potential therapeutic target}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4891|250px||COVID-19 AOP}} | ||
| + | Experimental pathway to investigate overlap of virus-host interaction and adverse outcome pathways | ||
| + | |width=100px|{{#pwImage:Pathway:WP4884|250px||nsp9/nsp10-mediated SARS-CoV-2 pathogenesis}} | ||
| + | Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis | ||
| + | |- | ||
| + | |} | ||
| + | {| style="margin: 10px; background-color:#AFDCDE" | ||
| + | |width=100px|{{#pwImage:Pathway:WP4904|250px||LDLRAD4 pathway in COVID-19}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4936|250px||Overview of perturbations to host-cell autophagy, induced by distinct proteins of SARS-CoV-2 (Homo sapiens)}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4961|250px||STING pathway in Kawasaki-like disease and COVID-19 (Homo sapiens)}} | ||
| + | |- | ||
| + | |} | ||
| + | |||
| + | == Other coronaviruses: MERS, SARS-CoV, etc == | ||
| + | |||
| + | {| style="margin: 10px; background-color:#AFDCDE" | ||
|width=100px|{{#pwImage:Pathway:WP4853|250px||Coronavirus lipid metabolism}} | |width=100px|{{#pwImage:Pathway:WP4853|250px||Coronavirus lipid metabolism}} | ||
| + | Lipid metabolism alternations that are related to infection by the corona virus. | ||
| + | |width=100px|{{#pwImage:Pathway:WP4863|250px||Host-pathogen interaction of human corona viruses - autophagy}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4864|250px||Host-pathogen interaction of human corona viruses - apoptosis}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4912|250px||SARS coronavirus and innate immunity}} | ||
| + | |- | ||
| + | |} | ||
| + | {| style="margin: 10px; background-color:#AFDCDE" | ||
| + | |width=100px|{{#pwImage:Pathway:WP4861|250px||ER stress response in Coronavirus infection}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4799|250px||Downregulation of ACE2 expression by SARS-CoV infection and SARS-CoV Spike protein}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4877|250px||Host-pathogen interaction of human corona viruses - MAPK signaling}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4880|250px||Host-pathogen interaction of human corona viruses - Interferon induction}} | ||
| + | |- | ||
| + | |} | ||
| + | {| style="margin: 10px; background-color:#AFDCDE" | ||
| + | |width=100px|{{#pwImage:Pathway:WP4965|250px||Deregulation of the Renin Angiotensin system by Sars-CoV infection}} | ||
| + | |- | ||
| + | |} | ||
| + | |||
| + | == More about ACE2 == | ||
| + | |||
| + | {| style="margin: 10px; background-color:#AFDCDE" | ||
| + | |width=100px|{{#pwImage:Pathway:WP554|250px||ACE Inhibitor Pathway}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP2729|250px||Metabolism of Angiotensinogen to Angiotensins (Reactome)}} | ||
|- | |- | ||
|} | |} | ||
Current revision
- REDIRECT Portal:COVID-19
|
This special subset of disease pathways is being highlighted during the current COVID-19 crisis. This content is released under a CC0 waiver to be freely used, reused and distributed. Let us know if you add a new pathway or want to recommend one for this collection. The current list of authors and contributors of content of this portal: Friederike Ehrhart, Alex Pico, Kristina Hanspers, Amber Koning, Rex D A B, Penny Nymark, Denise Slenter, Caroline Thorn, Jordi Doijen, the Reactome project, Chris Evelo, Lauren Dupuis, Matthew Conroy, Martina Kutmon, Marvin Martens, and many more. We also thank the authors of all the cited articles (recursively).
|
 Part of the COVID-19 Disease Map project A paper about this project was published in Scientific Data. |
SARS-CoV-2 Pathways
|
Image does not exist SARS-CoV-2 and COVID-19 Pathway Collaborative project for curation of biological processes involved in the COVID-19 disease after SARS-Cov-2 infection. |
Image does not exist Hijack of Ubiquitination by SARS-CoV-2 SARS-CoV-2 includes a novel Orf10 that interacts with muliple members of the Cullin 2 ubiquitin ligase complex. |
Image does not exist Type I Interferon Induction and Signaling During SARS-CoV-2 Infection The induction and signaling of type I interferon with specific SARS-CoV-2 protein and relevant drug. |
Image does not exist COVID-19, thrombosis and anticoagulation |
|
Image does not exist Activation of NLRP3 Inflammasome by SARS-CoV-2 Orf3a from SARS-CoV has been shown to bind TRAF3 and activate the NLRP3 inflammasome. |
Image does not exist SARS-CoV-2 and Angiotensin-converting enzyme 2 (ACE2) receptor : Molecular mechanisms and potential therapeutic target |
Image does not exist COVID-19 AOP Experimental pathway to investigate overlap of virus-host interaction and adverse outcome pathways |
Image does not exist nsp9/nsp10-mediated SARS-CoV-2 pathogenesis Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis |
|
Image does not exist LDLRAD4 pathway in COVID-19 |
Image does not exist Overview of perturbations to host-cell autophagy, induced by distinct proteins of SARS-CoV-2 (Homo sapiens) |
Image does not exist STING pathway in Kawasaki-like disease and COVID-19 (Homo sapiens) |
Other coronaviruses: MERS, SARS-CoV, etc
|
Image does not exist Coronavirus lipid metabolism Lipid metabolism alternations that are related to infection by the corona virus. |
Image does not exist Host-pathogen interaction of human corona viruses - autophagy |
Image does not exist Host-pathogen interaction of human corona viruses - apoptosis |
Image does not exist SARS coronavirus and innate immunity |
|
Image does not exist ER stress response in Coronavirus infection |
Image does not exist Downregulation of ACE2 expression by SARS-CoV infection and SARS-CoV Spike protein |
Image does not exist Host-pathogen interaction of human corona viruses - MAPK signaling |
Image does not exist Host-pathogen interaction of human corona viruses - Interferon induction |
|
Image does not exist Deregulation of the Renin Angiotensin system by Sars-CoV infection |
More about ACE2
|
Image does not exist ACE Inhibitor Pathway |
Image does not exist Metabolism of Angiotensinogen to Angiotensins (Reactome) |
